306 related articles for article (PubMed ID: 35511392)
21. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
22. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
23. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria.
Bolm L; Pisuchpen N; Qadan M; Kambadakone A; Sondermann S; Mueller K; Petruch N; May K; Zelga P; Nebbia M; Michelakos T; Baba T; Roldan J; Harrison JM; Honselmann KC; Keck T; Lillemoe KD; Ferrone CR; Wellner UF; Fernandez-Del Castillo C
Ann Surg; 2022 Aug; 276(2):215-221. PubMed ID: 36036988
[TBL] [Abstract][Full Text] [Related]
24. Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable Survival.
Tjaden C; Hinz U; Klaiber U; Heger U; Springfeld C; Goeppert B; Schmidt T; Mehrabi A; Strobel O; Berchtold C; Schneider M; Diener M; Neoptolemos JP; Hackert T; Büchler MW
Ann Surg; 2023 Jan; 277(1):e112-e118. PubMed ID: 34171863
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
26. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
29. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
[TBL] [Abstract][Full Text] [Related]
30. Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Zhang Y; Frampton AE; Cohen P; Kyriakides C; Bong JJ; Habib NA; Spalding DR; Ahmad R; Jiao LR
J Gastrointest Surg; 2012 Oct; 16(10):1875-82. PubMed ID: 22878786
[TBL] [Abstract][Full Text] [Related]
31. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins.
Hernandez J; Mullinax J; Clark W; Toomey P; Villadolid D; Morton C; Ross S; Rosemurgy A
Ann Surg; 2009 Jul; 250(1):76-80. PubMed ID: 19561479
[TBL] [Abstract][Full Text] [Related]
32. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
[TBL] [Abstract][Full Text] [Related]
33. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma.
Zhang B; Lee GC; Qadan M; Fong ZV; Mino-Kenudson M; Desphande V; Malleo G; Maggino L; Marchegiani G; Salvia R; Scarpa A; Luchini C; De Gregorio L; Ferrone CR; Warshaw AL; Lillemoe KD; Bassi C; Castillo CF
Ann Surg; 2021 Aug; 274(2):e134-e142. PubMed ID: 31851002
[TBL] [Abstract][Full Text] [Related]
34. Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer.
Yin Z; Zhou Y; Hou B; Ma T; Yu M; Zhang C; Lu X; Jian Z
J Gastrointest Surg; 2018 Sep; 22(9):1565-1575. PubMed ID: 29777452
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
[TBL] [Abstract][Full Text] [Related]
36. R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma.
Crippa S; Giannone F; Schiavo Lena M; Belfiori G; Partelli S; Tamburrino D; Delpini R; Pagnanelli M; Pecorelli N; Balzano G; Doglioni C; Falconi M
Ann Surg Oncol; 2021 Aug; 28(8):4602-4612. PubMed ID: 33393031
[TBL] [Abstract][Full Text] [Related]
37. Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma? A meta-analysis.
Barreto SG; Pandanaboyana S; Ironside N; Windsor JA
HPB (Oxford); 2017 Jul; 19(7):573-579. PubMed ID: 28420560
[TBL] [Abstract][Full Text] [Related]
38. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
[TBL] [Abstract][Full Text] [Related]
39. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Wei AC; Ou FS; Shi Q; Carrero X; O'Reilly EM; Meyerhardt J; Wolff RA; Kindler HL; Evans DB; Deshpande V; Misdraji J; Tamm E; Sahani D; Moore M; Newman E; Merchant N; Berlin J; Goff LW; Pisters P; Posner MC
Ann Surg Oncol; 2019 Dec; 26(13):4489-4497. PubMed ID: 31418130
[TBL] [Abstract][Full Text] [Related]
40. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review.
Petrucciani N; Nigri G; Debs T; Giannini G; Sborlini E; Antolino L; Aurello P; D'Angelo F; Gugenheim J; Ramacciato G
Pancreatology; 2016; 16(6):1037-1043. PubMed ID: 27697467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
